ASPIRE (A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intranasal esketamine in addition to comprehensive standard of care for the rapid reduction of the symptoms of major depressive disorder, including suicidal ideation, in subjects assessed to be at imminent risk for suicide) Investigators Jeffrey I. Bennett, MD (Faculty, Adult Division) Vinod Alluri, MD (Faculty, Adult Division) Michelle Gates, PhD (Faculty, Division of Clinical Psychology) Santosh Shrestha, MD (Faculty, Adult Division) Arindam Chakrabarty, MD (Resident) Background: Major